A new preclinical study indicates that cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, could play a role in reducing neuroinflammation associated with Alzheimer’s disease — a key factor in the disorder’s progression.

The research, published in the journal eNeuro, found that inhaled CBD helped lower levels of pro-inflammatory molecules in a mouse model of Alzheimer’s, offering early evidence that it may be useful as a therapeutic option for managing neuroinflammation in the brain.

CBD’s Potential Role in Neuroinflammation

CBD is one of more than 100 compounds found in the cannabis plant, but unlike tetrahydrocannabinol (THC), it does not produce psychoactive effects.
Previous studies have shown that CBD has anti-inflammatory and antioxidant properties, and it has been explored for use in treating conditions such as epilepsy, anxiety, chronic pain, migraine, PTSD, and cancer-related symptoms.

Now, researchers at Augusta University in Georgia are examining its potential in neurodegenerative disorders like Alzheimer’s disease.

“Our group has studied the therapeutic potential of CBD for several years and found that inhaled CBD offers superior efficacy compared to oral or injected forms,” said Dr. Babak Baban, PhD, MPH, MBA, professor of immunology at Augusta University and lead author of the study.
“Given these findings, we wanted to see if CBD could help reduce neuroinflammation in Alzheimer’s disease — one of the most complex and devastating neurological conditions.”

Targeting Inflammation Beyond Amyloid and Tau

Dr. Baban noted that decades of Alzheimer’s research have focused primarily on amyloid plaques and tau tangles, but neither has led to a definitive cure.
“Alzheimer’s is not driven by a single mechanism,” he explained. “It involves multiple, interacting biological processes — including chronic inflammation. Exploring new therapeutic pathways like CBD may open the door to addressing the disease’s root causes.”

The researchers found that inhaled CBD significantly reduced the activity of two major immune signaling pathways — IDO (Indoleamine 2,3-dioxygenase) and cGAS-STING — both of which are known to amplify brain inflammation.
By suppressing these pathways, CBD helped calm overactive immune responses and restore balance in the brain’s inflammatory environment.

“This finding shows that CBD can modulate two critical immune ‘alarm’ systems,” Dr. Baban said. “It represents a potential shift from simply managing symptoms to targeting the underlying immune dysfunction that accelerates Alzheimer’s progression.”

Early but Promising Results

The study authors emphasized that the research is in its early stages and limited to animal models.
Dr. Baban’s team is now preparing translational studies to test inhaled CBD therapy in human participants with Alzheimer’s disease.

“We currently hold an active FDA Investigational New Drug (IND) application for CBD inhalation therapy,” Baban noted. “Our next step is to evaluate its safety, dosing, and effects on immune pathways in clinical settings.”

Expert Perspectives

Independent experts say the research offers an interesting perspective on Alzheimer’s treatment.
Dr. Megan Glenn, a clinical neuropsychologist at Hackensack Meridian Neuroscience Institute, said the study represents an important step forward by focusing on inflammation rather than amyloid buildup alone.

“What’s compelling is the direct link between immune pathway modulation — IDO and cGAS — and measurable behavioral improvements in the mice,” Dr. Glenn said. “It gives us new ways to think about Alzheimer’s beyond traditional approaches.”

However, Dr. Clifford Segil, a neurologist at Providence Saint John’s Health Center in California, cautioned that CBD’s potential in treating neurological conditions remains controversial and unproven in humans.

“While CBD may show anti-inflammatory effects in mice, applying this to humans — especially in neurodegenerative conditions like Alzheimer’s — is a big leap,” he said. “More evidence is needed before recommending it clinically.”

Looking Ahead

Researchers agree that while these early findings are promising, human clinical trials will be crucial to determine whether CBD can safely and effectively reduce neuroinflammation in people with Alzheimer’s disease.
If future studies confirm its benefits, inhaled CBD could become a novel, non-psychoactive therapeutic tool targeting one of Alzheimer’s most challenging mechanisms — chronic inflammation.

Source: Medical News Today – “CBD may help treat and reduce inflammation in Alzheimer’s disease”